Jeb Keiper, Nimbus Therapeutics CEO
Nimbus is back for more, raising $210M to fuel pipeline seven months after $4B Takeda deal
What kind of biotech company returns billions to its investors without ever opening a lab, commercializing a drug, or going public with an IPO? …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
